Ono Pharmaceutical has announced a partnership with US AI drug discovery company Aitia. The companies will use digital twins to identify targets in neurological disease. Hodogaya Chemical has established nucleic acid therapeutics CDMO subsidiary NuChord and will build a new facility at its Koriyama Plant to create an integrated service platform.
Ono Pharmaceutical announced on 2 September that it had entered into a drug discovery partnership agreement with US AI drug discovery company Aitia focused on neurological disease. Under the partnership, Aitia will use its proprietary AI technology to build digital twins and identify new therapeutic targets and biomarkers. Ono Pharmaceutical holds worldwide exclusive option rights to research, develop and commercialize drug candidates against targets identified by Aitia.
Hodogaya Chemical announced on 2 September that it had established NuChord, a subsidiary engaged in the nucleic acid therapeutics CDMO business. The company plans to build a new facility at its Koriyama Plant equipped with active pharmaceutical ingredient manufacturing equipment and cleanrooms, creating a one-stop service platform for customers in Japan and overseas that covers everything from raw materials through GMP manufacturing.